↓ Skip to main content

Evaluation of the new TNM-staging system for thymic malignancies: impact on indication and survival

Overview of attention for article published in World Journal of Surgical Oncology, December 2017
Altmetric Badge

Mentioned by

twitter
1 X user

Readers on

mendeley
40 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Evaluation of the new TNM-staging system for thymic malignancies: impact on indication and survival
Published in
World Journal of Surgical Oncology, December 2017
DOI 10.1186/s12957-017-1283-4
Pubmed ID
Authors

Michael Ried, Maria-Magdalena Eicher, Reiner Neu, Zsolt Sziklavari, Hans-Stefan Hofmann

Abstract

The objective of this study is the evaluation of the Masaoka-Koga and the International Association for the Study of Lung Cancer (IASLC)/International Thymic Malignancy Interest Group (ITMIG) proposal for the new TNM-staging system on clinical implementation and prognosis of thymic malignancies. A retrospective study of 76 patients who underwent surgery between January 2005 and December 2015 for thymoma. Kaplan-Meier survival analysis was used to determine overall and recurrence-free survival rates. Indication for surgery was primary mediastinal tumor (n = 55), pleural manifestation (n = 17), or mediastinal recurrence (n = 4) after surgery for thymoma. Early Masaoka-Koga stages I (n = 9) and II (n = 14) shifted to the new stage I (n = 23). Advanced stages III (Masaoka-Koga: n = 20; ITMIG/IASLC: n = 17) and IV (Masaoka-Koga: n = 33; ITMIG/IASLC: n = 35) remained nearly similar and were associated with higher levels of WHO stages. Within each staging system, the survival curves differed significantly with the best 5-year survival in early stages I and II (91%). Survival for stage IV (70 to 77%) was significantly better compared to stage III (49 to 54%). Early stages had a significant longer recurrence-free survival (86 to 90%) than advanced stages III and IV (55 to 56%). The proportion of patients with IASLC/ITMIG stage I increased remarkably, whereas the distribution in advanced stages III and IV was nearly similar. The new TNM-staging system presents a clinically useful and applicable system, which can be used for indication, stage-adapted therapy, and prediction of prognosis for overall and recurrence-free survival.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 40 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 8 20%
Student > Master 6 15%
Other 4 10%
Student > Doctoral Student 4 10%
Student > Bachelor 3 8%
Other 9 23%
Unknown 6 15%
Readers by discipline Count As %
Medicine and Dentistry 17 43%
Environmental Science 4 10%
Biochemistry, Genetics and Molecular Biology 2 5%
Agricultural and Biological Sciences 2 5%
Veterinary Science and Veterinary Medicine 1 3%
Other 5 13%
Unknown 9 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 January 2018.
All research outputs
#18,584,192
of 23,018,998 outputs
Outputs from World Journal of Surgical Oncology
#1,019
of 2,055 outputs
Outputs of similar age
#325,946
of 438,155 outputs
Outputs of similar age from World Journal of Surgical Oncology
#14
of 18 outputs
Altmetric has tracked 23,018,998 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,055 research outputs from this source. They receive a mean Attention Score of 2.1. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 438,155 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.